Peptides Similar to ACE-031

Peptides Related to ACE-031#

ACE-031 belongs to the emerging therapeutic category of myostatin pathway inhibitors, which aim to promote muscle growth by removing or reducing the natural myostatin-mediated brake on muscle development. Understanding how ACE-031 compares to other approaches in this space and to alternative muscle growth strategies provides important context for evaluating its place in therapeutic development.

Myostatin Pathway Inhibitors#

ACE-031 vs. Luspatercept (ACE-536 / Reblozyl)#

Luspatercept is the direct successor to ACE-031, developed by the same company (Acceleron Pharma, later acquired by Merck) using lessons learned from ACE-031's safety failures.

Luspatercept demonstrates how targeted protein engineering can resolve safety issues identified with an earlier compound. By modifying specific residues in the ActRIIB domain, Acceleron reduced BMP9/10 binding while maintaining therapeutic binding to activins, shifting the clinical application from muscle wasting to erythropoiesis.

ACE-031 vs. Anti-Myostatin Antibodies#

Several monoclonal antibodies targeting myostatin have been developed as an alternative to the broad decoy receptor approach.

Domagruzumab (PF-06252616): An anti-myostatin antibody evaluated in clinical trials for limb-girdle muscular dystrophy and DMD. Unlike ACE-031, it binds only myostatin and does not affect activins, BMPs, or GDF-11, providing a cleaner safety profile but potentially less potent muscle effects.

Stamulumab (MYO-029): An earlier anti-myostatin antibody from Wyeth that was evaluated in adult muscular dystrophies. Clinical results were disappointing, with no significant improvement in muscle strength despite biological evidence of myostatin inhibition.

ACE-031 vs. Myostatin Propeptide#

Myostatin is naturally inhibited by its propeptide, which remains bound to the mature ligand in an inactive latent complex. Engineered myostatin propeptides with enhanced binding affinity have been developed as therapeutic candidates. These offer specificity for myostatin over other TGF-beta ligands, an endogenous inhibitory mechanism, and potentially better safety profiles than broad-spectrum approaches. However, they have less potent effects compared to broad ActRIIB inhibition and limited clinical development to date.

Endogenous Myostatin Regulators#

ACE-031 vs. Follistatin#

Follistatin is an endogenous protein that naturally inhibits activin and myostatin by binding them in the circulation. It represents the body's own regulatory mechanism for controlling TGF-beta superfamily signaling.

• Gene therapy approach: Follistatin gene therapy (AAV-FS344) has been evaluated in clinical trials for Becker muscular dystrophy and inclusion body myositis, showing promise with localized muscle improvement
• Binding profile: Follistatin binds activin with highest affinity, followed by myostatin; it does not strongly bind BMP9/10, providing a better safety profile than ACE-031
• Natural regulation: As an endogenous protein, follistatin is already part of the normal regulatory network, potentially reducing the risk of unexpected effects

ACE-031 vs. GASP-1/FLRG#

Growth and differentiation factor-associated serum proteins (GASP-1) and follistatin-related gene (FLRG) are additional endogenous inhibitors of myostatin. These proteins contribute to the natural regulatory network that controls myostatin activity but have received less therapeutic development attention than follistatin or engineered inhibitors.

Alternative Muscle Growth Strategies#

ACE-031 vs. IGF-1#

Insulin-like growth factor 1 (IGF-1) promotes muscle growth through a completely different pathway, directly stimulating anabolic signaling through the IGF-1 receptor and PI3K/Akt/mTOR cascade.

• Mechanism: IGF-1 directly activates muscle protein synthesis; ACE-031 removes the inhibitory signal on muscle growth
• Clinical status: Recombinant IGF-1 (mecasermin) is FDA-approved for growth hormone insensitivity
• Side effects: IGF-1 causes hypoglycemia, which is not a concern with myostatin pathway inhibitors
• Complementarity: IGF-1 and myostatin pathway inhibition target different aspects of muscle regulation and could theoretically be complementary

ACE-031 vs. SARMs (Selective Androgen Receptor Modulators)#

SARMs represent a pharmacological approach to muscle growth through selective activation of androgen receptors in muscle tissue.

• Mechanism: SARMs directly activate androgen receptor-mediated gene expression in muscle; ACE-031 removes TGF-beta-mediated growth inhibition
• Selectivity: SARMs aim for tissue-selective androgen effects; ACE-031 targets a completely different pathway
• Clinical status: Several SARMs have reached clinical trials for muscle wasting; none are FDA-approved for this indication
• Combination potential: SARMs and myostatin inhibitors target different pathways and could potentially be combined

Evidence Comparison#

Evidence Gaps#

The field of myostatin pathway inhibition continues to face a central paradox: preclinical evidence consistently demonstrates dramatic muscle growth with myostatin inhibition, yet clinical translation has been challenging. Neither ACE-031 nor any other myostatin inhibitor has achieved regulatory approval for a muscle wasting indication. The evidence gaps include the lack of an approved myostatin pathway inhibitor for any neuromuscular disease, the disconnect between body composition changes and functional improvement in clinical trials, and the need for more selective inhibitors that avoid off-target effects while maintaining muscle efficacy.

Related Reading#

• ACE-031 overview and research guide
• ACE-031 research evidence
• ACE-031 dosing protocols